U.S. pharma huge copyright scrapped two experimental weight loss tablets very last yr—a at the time-each day tablet, lotiglipron, due to elevated liver enzymes and also a twice-each day tablet, danuglipron, due to robust side effects—but CEO Albert Bourla has reported the company is determined to “Perform and acquire” from the weight proble